Hypersensitivity to the active substance, to boron or mannitol (E421) and of the excipients.
Acute diffuse infiltrative pulmonary and pericardial disease.
When bortezomib is given in combination with other medicinal products, refer to their Summaries of Product Characteristics for additional contraindications.